Andrew Reardon
CLO & Secretary · LIGAND PHARMACEUTICALS INC
- 2025
- Oct 6, 2026
- 12
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Andrew Reardon files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Octavio Espinoza - $13.03M in LGND purchases and sales in the last 12 months
- Jason Haas - $3.74M in LGND purchases and sales in the last 12 months
- John L. Lamattina - $2.44M in LGND purchases and sales in the last 12 months
- Nancy Ryan Gray - $1.35M in LGND purchases and sales in the last 12 months
- Jason Aryeh - $1.25M in LGND purchases and sales in the last 12 months
- Stephen L. Sabba - $1.16M in LGND purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Andrew Reardon?
Andrew Reardon is a corporate insider, tracked as CLO & Secretary of LIGAND PHARMACEUTICALS INC (LGND). InsiderAlpha holds 12 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Andrew Reardon submitted recently?
3 primary Form 4 filings in the last 90 days, covering 1 company.
Has Andrew Reardon been buying or selling stock?
Recorded transactions: 0 open-market purchases and 60 open-market sales ($10.29M) across all tracked filings.
